Author

C. D. Tristan

View on Semantic Scholar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jul 2026

Early Catheter Ablation for Atrial Fibrillation After Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis with Reconstructed Kaplan-Meier Individual Patient Data.

BACKGROUND Catheter ablation (CA) for atrial fibrillation (AF) reduces mortality and heart failure (HF) hospitalizations in stable chronic HF, but optimal timing following acute decompensated heart failure (ADHF) remains uncertain. This meta-analysis aimed to evaluate whether early CA reduces mortality, rehospitalization, and improves cardiac function compared with delayed or no ablation. METHODS We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. PubMed and Scopus databases were searched through December 16, 2025. Studies reporting outcomes of CA performed during ADHF hospitalization or within 90 days post-discharge were included. RESULTS Four studies (n=396 patients, 221 early ablation) were included. Qualitatively, early CA was consistently associated with improved clinical outcomes across included studies. Early CA improved left ventricular ejection fraction and reduced left atrial dimensions. Procedural complication rates were low with no significant difference between groups. Quantitatively, early CA significantly reduced the composite outcomes of cardiovascular mortality or HF rehospitalization (RR 0.35, 95% CI 0.17-0.70; p = 0.003). Reconstructed survival analysis demonstrated an association between early CA and higher event-free survival for the composite of cardiovascular death and HF-rehospitalization (HR 0.24, 95% CI 0.12-0.50; p < 0.0001) and all-cause mortality (HR 0.51, 95% CI 0.27-0.94; p = 0.033). CONCLUSIONS Early CA following ADHF was associated with substantial reductions in mortality or HF rehospitalization with acceptable safety. These findings suggest a potential role of early CA during or shortly after ADHF in hemodynamically stable patients, though randomized trials are needed to confirm efficacy and optimize patient selection.

Raymond Pranata, C. D. Tristan, E. Yonas et al. · Hellenic Journal of Cardiolo... · 1 citation

Open access Aug 2026

Exploration of Compounds Identified from Amomum cardamomum Seed Extract: LC-MS Profiling, Network Pharmacology, and Computational Analyses for Innovative Multi-Targeted Breast Cancer Therapy

Background Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and the emergence of drug resistance, systemic toxicity, and limited efficacy of current therapies highlight the need for safer and more effective treatment. Natural products have emerged as promising sources of multi-target anticancer agents. A. cardamomum has demonstrated preliminary anticancer potential, yet the bioactive constituents and their molecular mechanisms in breast cancer remain poorly elucidated. Methods This study integrated in silico approaches to investigate the therapeutic potential of A. cardamomum seed extract against breast cancer. LC–MS analysis identified phytochemical compounds, followed by network pharmacology to determine their potential targets and molecular pathways. Pharmacokinetic and toxicity predictions were assessed through ADMET and Lipinski’s rule of five analyses to evaluate drug-likeness and safety. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding affinity and structural stability of compounds with key oncogenic proteins. Results LC-MS profiling identified 22 distinct compounds in A. cardamomum seeds. ADMET and Lipinski analyses demonstrated that most compounds possessed high gastrointestinal absorption, favorable oral bioavailability, and low toxicity risk. Network pharmacology highlighting SRC, TNF-α, Caspase-3, and EGFR as central nodes in the protein-protein interaction network. Molecular docking identified compounds C17 and C20 as the most promising bioactives, showing strong binding affinities and interactions similar to control ligands. MD simulations confirmed their stable complexes, indicating conformational stability and robust ligand–protein interactions. Conclusion This study highlights the promising multi-target anticancer potential of A. cardamomum seeds. Compounds C17 and C20 were identified as lead candidates with strong and stable interactions with key breast cancer-related proteins and favorable pharmacokinetic properties. These results suggest that A. cardamomum could serve as a potential source for developing new plant-based therapies against breast cancer. Further in vitro and in vivo investigations are warranted to validate their efficacy and safety.

Dessy Arisanty, S. Khairani, K. Cuandra et al. · F1000Research · 0 citations